B7-H4 Expression is Associated with Cancer Progression and Predicts Patient Survival in Human Thyroid Cancer

  • Zhu, Jian ;
  • Chu, Bing-Feng ;
  • Yang, Yi-Peng ;
  • Zhang, Sheng-Lai ;
  • Zhuang, Ming ;
  • Lu, Wen-Jie ;
  • Liu, Ying-Bin
  • Published : 2013.05.30


Objective: This study aimed to investigate the expression of B7-H4 in human thyroid cancer and determine any association with patient clinicopathological parameters and survival. Methods: B7-H4 expression in 64 clinical thyroid cancer specimens was assessed with immunohistochemistry. Moreover, B7-H4 mRNA expression in 10 fresh resected specimens were evaluated by the reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemical staining of CD3 was performed to assess the number of tumor infiltrating T lymphocytes (TILs) in thyroid cancers. Results: Positive B7-H4 immunohistochemical staining was observed in 61 out of 64 (95.3%) specimens of thyroid cancer tissues. Significantly more B7-H4 mRNA copies were found in thyroid cancer tissue than that adjacent normal tissue. Moreover, B7-H4 expression in human thyroid cancer tissues was significantly correlated with patient TNM stages and extrathyroidal extension (P<0.05), being inversely correlated with the number of TILs (P<0.05). The overall survival rate of the patients with higher B7-H4 expression was significantly worse than that of the patients with lower B7-H4 expression. Conclusions: This present study suggests that high B7-H4 expression is associated with cancer progression, reduced tumor immunosurveillance and worse patient outcomes in human thyroid cancer.


Thyroid cancer;B7-H4;progression;prognosis;tumor infiltrating lymphocytes


  1. Xie WC, Chan MH, Mak KC, et al (2012). Trends in the incidence of 15 common cancers in Hong Kong, 1983-2008. Asian Pac J Cancer Prev, 13, 3911-6.
  2. Xing M (2013). Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer, 13, 184-99.
  3. Zang X, Loke P, Kim J, et al (2003). B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A, 100, 10388-92.
  4. Zhang L, Wu H, Lu D, et al (2013). The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene, Jan 14. doi:10.1038/onc.2012.600. [Epub ahead of print].
  5. Zheng X, Li XD, Wu CP, et al (2012). Expression of costimulatory molecule B7-H4 in human malignant tumors. Onkologie, 35, 700-5.
  6. Abadi YM, Jeon H, Ohaegbulam KC, et al (2013). Host b7x promotes pulmonary metastasis of breast cancer. J Immunol, 190, 3806-14.
  7. Arigami T, Uenosono Y, Hirata M, et al (2010). Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J Surg Oncol, 102, 748-52.
  8. Arigami T, Uenosono Y, Ishigami S, et al (2011). Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J Surg, 35, 2051-7.
  9. Awadallah NS, Shroyer KR, Langer DA, et al (2008). Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct. Pancreas, 36, 200-6.
  10. Chen L (2004). Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol, 4, 336-47.
  11. Chen LJ, Sun J, Wu HY, et al (2011). B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother, 60, 1047-55.
  12. Flies DB, Chen L (2007). The new B7s: playing a pivotal role in tumor immunity. J Immunother, 30, 251-60.
  13. Grabenbauer GG, Lahmer G, Distel L, et al (2006). Tumorinfiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res, 12, 3355-60.
  14. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  15. Miyatake T, Tringler B, Liu W, et al (2007). B7-H4 (DDO110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol, 106, 119-27.
  16. Oikonomopoulou K, Li L, Zheng Y, et al (2008). Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer, 99, 1103-13.
  17. Prasad DV, Richards S, Mai XM, et al (2003). B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity, 18, 863-73.
  18. Sica GL, Choi IH, Zhu G, et al (2003). B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity, 18, 849-61.
  19. Siegel R, Naishadham D & Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.
  20. Sun SQ, Jiang CG, Lin Y, et al (2012). Enhanced T cell immunity by B7-H4 downregulation in nonsmall-cell lung cancer cell lines. J Int Med Res, 40, 497-506.
  21. Tringler B, Zhuo S, Pilkington G, et al (2005). B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res, 11, 1842-8.
  22. Tuttle RM, Ball DW, Byrd D, et al (2010). Thyroid carcinoma. J Natl Compr Canc Netw, 8, 1228-74.

Cited by

  1. Emerging Co-signaling Networks in T Cell Immune Regulation vol.13, pp.5, 2013,
  2. Aberrant expression of B7-H4 correlates with poor prognosis and suppresses tumor-infiltration of CD8+ T lymphocytes in human cholangiocarcinoma vol.36, pp.1, 2016,
  3. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3 vol.276, pp.1, 2017,
  4. Potential targeting of B7-H4 for the treatment of cancer vol.276, pp.1, 2017,
  5. New checkpoints in cancer immunotherapy vol.276, pp.1, 2017,
  6. Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10 vol.66, pp.6, 2017,